Biotech · Private company
Arena Pharmaceuticals
Track this companyFree. Adds Arena Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials120 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- EtrasimodPhase 3 · Ulcerative ColitisClinicalTrials.gov · fetched Nov 12, 2026
- APD125Phase 2 · Primary InsomniaClinicalTrials.gov · fetched Nov 12, 2026
- APD334Phase 2 · Primary Biliary CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- APD356-lorcaserin hydrochloridePhase 2 · Smoking CessationClinicalTrials.gov · fetched Nov 12, 2026
- Etrasimod 1 mgPhase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Etrasimod 2 mgPhase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- OlorinabPhase 2 · Crohn's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- OlorinabPhase 2 · Irritable Bowel SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- APD791Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel SyndromePHASE1 · TERMINATED · started Jan 29, 2021ClinicalTrials.gov NCT04655599 · fetched Nov 12, 2026
- Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisPHASE3 · COMPLETED · started Sep 15, 2020ClinicalTrials.gov NCT03996369 · fetched Nov 12, 2026
- A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic DermatitisPHASE2 · COMPLETED · started Oct 4, 2019ClinicalTrials.gov NCT04162769 · fetched Nov 12, 2026
- Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)PHASE2 · TERMINATED · started Jul 24, 2019ClinicalTrials.gov NCT04043455 · fetched Nov 12, 2026
- Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisPHASE3 · COMPLETED · started Jun 13, 2019ClinicalTrials.gov NCT03945188 · fetched Nov 12, 2026
- Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary CholangitisPHASE2 · TERMINATED · started Dec 29, 2017ClinicalTrials.gov NCT03155932 · fetched Nov 12, 2026
- Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal PainPHASE2 · COMPLETED · started Jul 19, 2017ClinicalTrials.gov NCT03155945 · fetched Nov 12, 2026
- Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisPHASE2 · COMPLETED · started Jan 25, 2016ClinicalTrials.gov NCT02536404 · fetched Nov 12, 2026
- Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative ColitisPHASE2 · COMPLETED · started Oct 15, 2015ClinicalTrials.gov NCT02447302 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking CessationPHASE2 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT02044874 · fetched Nov 12, 2026
- Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance InsomniaPHASE2 · COMPLETED · started Apr 1, 2008ClinicalTrials.gov NCT00664664 · fetched Nov 12, 2026
- A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy VolunteersPHASE1 · COMPLETED · started Jan 1, 2008ClinicalTrials.gov NCT00619931 · fetched Nov 12, 2026